The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.
A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Starting and Monitoring Medications in Fragile X Syndrome — Presentation
Learn how to navigate medication strategies and approaches for children with FXS. Presented by Karen Regan, RN, and Nicole Tartaglia, MD.
EXPERIENCE Clinical Trials in Fragile X Syndrome
Shionogi's clinical trials for males aged 9–45 living with FXS with a molecular genetic confirmation FMR1 >200 CGG repetitions testing a new drug zatolmilast.